Wednesday, September 27, 2023 at 2-3 pm ET                 Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Goal directed therapy is foundational to rational pharmacotherapy as well as the development of treatment guidelines. Importantly, treatment goals are not static and must evolve as a function of an evolving understanding of a given disease and the availability of more effective treatments. Innovations in rheumatology are enabling more patients to achieve higher levels of response and continue to facilitate the research necessary to define and refine treatment goals over time. For example, the multitude of high-quality clinical trials with TNF inhibitors provided much of the data necessary to categorically define the treatment goals of low disease activity and remission, which now form the backbone of treat-to-target strategies found in ACR and EULAR RA treatment guidelines. Similarly, development of new mechanisms of action to treat psoriatic arthritis and axial spondyloarthritis (ax-SpA) have provided fertile resources to evaluate and develop new treatment goals for patients afflicted with these conditions.

The objective of this webinar is to review the evolution of goal directed therapy in rheumatology and discuss the clinical value of goal-directed therapy and how payers can support goal-directed therapy.

Learning Objectives

• Review current treatment goals in rheumatology, progress toward goal attainment, and current practice patterns in rheumatology.
• Describe the clinical value of achieving treatment goals in rheumatology and how payers can support goal directed therapy to improve the value of targeted immunomodulator therapies.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

US Medical Affairs

For individuals from the media/press interested in attending, please email media@amcp.org.